CY1118663T1 - Μεθοδος αναγνωρισης κινδυνου για διαταραχη του θυρεοειδους - Google Patents
Μεθοδος αναγνωρισης κινδυνου για διαταραχη του θυρεοειδουςInfo
- Publication number
- CY1118663T1 CY1118663T1 CY20171100113T CY171100113T CY1118663T1 CY 1118663 T1 CY1118663 T1 CY 1118663T1 CY 20171100113 T CY20171100113 T CY 20171100113T CY 171100113 T CY171100113 T CY 171100113T CY 1118663 T1 CY1118663 T1 CY 1118663T1
- Authority
- CY
- Cyprus
- Prior art keywords
- patient
- thyroid
- risk
- developing
- treatment
- Prior art date
Links
- 208000024799 Thyroid disease Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 208000021510 thyroid gland disease Diseases 0.000 title 1
- 108010036012 Iodide peroxidase Proteins 0.000 abstract 2
- 102000014267 Thyroid peroxidases Human genes 0.000 abstract 2
- 210000001589 microsome Anatomy 0.000 abstract 2
- 210000001685 thyroid gland Anatomy 0.000 abstract 2
- 102000013135 CD52 Antigen Human genes 0.000 abstract 1
- 108010065524 CD52 Antigen Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70592—CD52
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/046—Thyroid disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Μία μέθοδος για την αναγνώριση ενός ασθενούς, ο οποίος βρίσκεται σε κίνδυνο για την ανάπτυξη μιας διαταραχής του θυρεοειδούς, η οποία εμφανίζεται μετά την θεραπεία με μία αγωγή που εξαντλεί τα λεμφοκύτταρα, η οποία περιλαμβάνει τον προσδιορισμό, εάν τα αντισώματα, τα οποία κατευθύνονται εναντίον της υπεροξειδάσης του θυρεοειδούς ή των μικροσωμάτων του θυρεοειδούς είναι παρόντα στον ασθενή, όπου εάν τα αντισώματα είναι παρόντα στον ασθενή, τότε ο ασθενής βρίσκεται σε αυξημένο κίνδυνο για την ανάπτυξη μιας διαταραχής του θυρεοειδούς. Μία συγκεκριμένη εφαρμογή είναι μία μέθοδος για την αναγνώριση ενός ασθενούς με σκλήρυνση κατά πλάκας, ο οποίος βρίσκεται σε κίνδυνο για την ανάπτυξη μιας διαταραχής του θυρεοειδούς, που συμβαίνει μετά την θεραπεία με μία αγωγή που εξαντλεί τα CD52-θετικά κύτταρα, που περιλαμβάνει τον προσδιορισμό, εάν τα αντισώματα τα οποία κατευθύνονται εναντίον της υπεροξειδάσης του θυρεοειδούς ή των μικροσωμάτων του θυρεοειδούς είναι παρόντα στον ασθενή, όπου, εάν τα αντισώματα είναι παρόντα στον ασθενή, τότε ο ασθενής βρίσκεται σε κίνδυνο για την ανάπτυξη της διαταραχής του θυρεοειδούς.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90173207P | 2007-02-16 | 2007-02-16 | |
| PCT/US2008/002047 WO2008103292A1 (en) | 2007-02-16 | 2008-02-15 | Method of identifying risk for thyroid disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118663T1 true CY1118663T1 (el) | 2017-07-12 |
Family
ID=39434244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100113T CY1118663T1 (el) | 2007-02-16 | 2017-01-26 | Μεθοδος αναγνωρισης κινδυνου για διαταραχη του θυρεοειδους |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20100136587A1 (el) |
| EP (2) | EP2130044B1 (el) |
| JP (2) | JP5662684B2 (el) |
| CN (2) | CN101657721B (el) |
| AU (1) | AU2008219097B2 (el) |
| BR (1) | BRPI0807601B8 (el) |
| CA (1) | CA2678199A1 (el) |
| CY (1) | CY1118663T1 (el) |
| DK (1) | DK2130044T3 (el) |
| ES (1) | ES2612558T3 (el) |
| HR (1) | HRP20170121T1 (el) |
| HU (1) | HUE031421T2 (el) |
| IL (2) | IL200314A (el) |
| LT (1) | LT2130044T (el) |
| MX (1) | MX2009008642A (el) |
| PL (1) | PL2130044T3 (el) |
| PT (1) | PT2130044T (el) |
| RS (1) | RS55636B1 (el) |
| RU (1) | RU2013120485A (el) |
| SI (1) | SI2130044T1 (el) |
| WO (1) | WO2008103292A1 (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| FR2934129B1 (fr) * | 2008-07-24 | 2014-05-02 | Oreal | Procede de traitement cosmetique. |
| EP2335066B1 (en) * | 2008-09-19 | 2016-12-28 | University of Utah Research Foundation | Methods for prediction of multiple sclerosis disease and therapy response |
| CN106257288A (zh) * | 2016-08-15 | 2016-12-28 | 余洋 | 一种血清TPOAb IgG4水平检测方法 |
| EP3817761B1 (en) | 2018-07-02 | 2025-04-02 | Siemens Healthcare Diagnostics Inc. | Novel thyroid peroxidase autoantibody immunoassay |
| KR102469743B1 (ko) | 2020-06-10 | 2022-11-22 | 주식회사 타이로스코프 | 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말 |
| EP4001919A1 (en) * | 2020-11-13 | 2022-05-25 | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | Predictive biomarkers of autoimmunity in patients treated with alemtuzumab |
| WO2024158259A1 (ko) * | 2023-01-27 | 2024-08-02 | 주식회사 타이로스코프 | 대상에 대한 갑상선기능이상증의 예측방법 및 시스템 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| GB2265713A (en) * | 1992-05-16 | 1993-10-06 | R S R Limited | Assay for autoantibodies against thyroglobulin or thyroid peroxidase |
| DE19710211C2 (de) * | 1997-03-12 | 1999-12-16 | Brahms Diagnostica Gmbh | Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern |
| GB9823397D0 (en) * | 1998-10-27 | 1998-12-23 | Rsr Ltd | Assays for thyroid autoantibodies |
| WO2006044332A2 (en) * | 2004-10-12 | 2006-04-27 | Carantech, Inc. | Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes |
| US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
-
2008
- 2008-02-15 HU HUE08725657A patent/HUE031421T2/hu unknown
- 2008-02-15 CN CN200880012149.4A patent/CN101657721B/zh active Active
- 2008-02-15 DK DK08725657.4T patent/DK2130044T3/en active
- 2008-02-15 SI SI200831753A patent/SI2130044T1/sl unknown
- 2008-02-15 HR HRP20170121TT patent/HRP20170121T1/hr unknown
- 2008-02-15 PT PT87256574T patent/PT2130044T/pt unknown
- 2008-02-15 JP JP2009549628A patent/JP5662684B2/ja active Active
- 2008-02-15 BR BRPI0807601A patent/BRPI0807601B8/pt active IP Right Grant
- 2008-02-15 CN CN201810058824.2A patent/CN108303546B/zh active Active
- 2008-02-15 EP EP08725657.4A patent/EP2130044B1/en active Active
- 2008-02-15 US US12/526,129 patent/US20100136587A1/en not_active Abandoned
- 2008-02-15 PL PL08725657T patent/PL2130044T3/pl unknown
- 2008-02-15 AU AU2008219097A patent/AU2008219097B2/en active Active
- 2008-02-15 LT LTEP08725657.4T patent/LT2130044T/lt unknown
- 2008-02-15 RS RS20170083A patent/RS55636B1/sr unknown
- 2008-02-15 WO PCT/US2008/002047 patent/WO2008103292A1/en not_active Ceased
- 2008-02-15 ES ES08725657.4T patent/ES2612558T3/es active Active
- 2008-02-15 MX MX2009008642A patent/MX2009008642A/es active IP Right Grant
- 2008-02-15 EP EP12176625A patent/EP2538217A1/en not_active Withdrawn
- 2008-02-15 CA CA002678199A patent/CA2678199A1/en not_active Withdrawn
-
2009
- 2009-08-10 IL IL200314A patent/IL200314A/en active IP Right Grant
-
2012
- 2012-12-05 US US13/705,944 patent/US9664688B2/en active Active
-
2013
- 2013-05-06 RU RU2013120485/15A patent/RU2013120485A/ru not_active Application Discontinuation
-
2014
- 2014-05-28 JP JP2014110361A patent/JP6058585B2/ja active Active
-
2015
- 2015-11-02 IL IL242391A patent/IL242391A/en active IP Right Grant
-
2017
- 2017-01-26 CY CY20171100113T patent/CY1118663T1/el unknown
- 2017-05-10 US US15/591,547 patent/US10648986B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118663T1 (el) | Μεθοδος αναγνωρισης κινδυνου για διαταραχη του θυρεοειδους | |
| CY1112739T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης | |
| CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
| CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
| CY1117859T1 (el) | Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης | |
| CY1120423T1 (el) | Β7-η1 και pd-1 στη θεραπεια του καρκινωματος νεφρικων κυτταρων | |
| CY1121294T1 (el) | Αντι-ilt7 αντισωμα | |
| CY1122593T1 (el) | Αντισωματα εναντι-cd40 και χρησεις αυτων | |
| EP3903447A4 (en) | AUTOMATIC VEHICLE IDENTITY VERIFICATION AND VEHICLE PRESENCE VALIDATION | |
| CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
| BR112016018205A2 (pt) | métodos de tratamento de mal de alzheimer | |
| CY1120665T1 (el) | Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους | |
| CY1120144T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| CY1124140T1 (el) | Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| CY1121335T1 (el) | Anti-cxcr3 αντισωματα | |
| EP1912674A4 (en) | BIS SPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHOD OF USE THEREOF | |
| ATE527385T1 (de) | Mit tumoren assoziierte genetische variationen | |
| CY1117784T1 (el) | Μεθοδοι και συνθεσεις για διαγνωση και προγνωση νεφρικης βλαβης και νεφρικης ανεπαρκειας | |
| TR201900160T4 (tr) | Bir anti-ilaç antikoru varlığının veya miktarının saptanmasına yönelik analizler. | |
| MY177564A (en) | Anti-nr10 antibody and use thereof | |
| CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
| BRPI0912927A2 (pt) | "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo" | |
| DOP2006000029A (es) | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) | |
| MA50079A (fr) | Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire |